Publications by authors named "Philip J Rybczynski"

12Publications

Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.

Authors:
Jay M Matthews Xiaoli Chen Ellen Cryan Dennis J Hlasta Philip J Rybczynski Kim Strauss Yuting Tang June Z Xu Maria Yang Lubing Zhou Keith T Demarest

Bioorg Med Chem Lett 2007 Dec 17;17(24):6773-8. Epub 2007 Oct 17.

Drug Discovery, Johnson & Johnson, East Coast RED, Spring House, PA 19477-0776, USA.

View Article and Find Full Text PDF
December 2007

Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.

Authors:
Min Amy Xiang Philip J Rybczynski Mona Patel Robert H Chen David F McComsey Han-Cheng Zhang Joseph W Gunnet Richard Look Yuanping Wang Lisa K Minor H Marlon Zhong Frank J Villani Keith T Demarest Bruce P Damiano Bruce E Maryanoff

Bioorg Med Chem Lett 2007 Dec 19;17(23):6623-8. Epub 2007 Sep 19.

Research and Early Development, Johnson & Johnson Pharmaceutical Research & Development, 8 Clarke Drive, Cranbury, NJ 08512, USA.

View Article and Find Full Text PDF
December 2007

Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.

Authors:
Xiaoyan Zhang Maud Urbanski Mona Patel Geoffrey G Cox Roxanne E Zeck Haiyan Bian Bruce R Conway Mary Pat Beavers Philip J Rybczynski Keith T Demarest

Bioorg Med Chem Lett 2006 Mar 27;16(6):1696-701. Epub 2005 Dec 27.

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
March 2006

Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.

Authors:
Xiaoyan Zhang Maud Urbanski Mona Patel Roxanne E Zeck Geoffrey G Cox Haiyan Bian Bruce R Conway Mary Pat Beavers Philip J Rybczynski Keith T Demarest

Bioorg Med Chem Lett 2005 Dec 28;15(23):5202-6. Epub 2005 Sep 28.

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
December 2005

Synthesis and evaluation of 3-anilino-quinoxalinones as glycogen phosphorylase inhibitors.

Authors:
Joseph Dudash Yongzheng Zhang John B Moore Richard Look Yin Liang Mary Pat Beavers Bruce R Conway Philip J Rybczynski Keith T Demarest

Bioorg Med Chem Lett 2005 Nov;15(21):4790-3

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
November 2005

Glycosylated dihydrochalcones as potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitors.

Authors:
Joseph Dudash Xiaoyan Zhang Roxanne E Zeck Sigmond G Johnson Geoffrey G Cox Bruce R Conway Philip J Rybczynski Keith T Demarest

Bioorg Med Chem Lett 2004 Oct;14(20):5121-5

Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Rt. 202, PO Box 300, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
October 2004

Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.

Authors:
Min Amy Xiang Robert H Chen Keith T Demarest Joseph Gunnet Richard Look William Hageman William V Murray Donald W Combs Philip J Rybczynski Mona Patel

Bioorg Med Chem Lett 2004 Jun;14(12):3143-6

Endocrine Therapeutics and Metabolic Disorders, Johnson and Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202, Bldg: PCC, Room: PC110, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
June 2004

Benzoxazinones as PPARgamma agonists. 2. SAR of the amide substituent and in vivo results in a type 2 diabetes model.

Authors:
Philip J Rybczynski Roxanne E Zeck Joseph Dudash Donald W Combs Thomas P Burris Maria Yang Melville C Osborne Xiaoli Chen Keith T Demarest

J Med Chem 2004 Jan;47(1):196-209

Johnson and Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, New Jersey 08869, USA.

View Article and Find Full Text PDF
January 2004

2,5-disubstituted 3,4-dihydro-2H-benzo[b][1,4]thiazepines as potent and selective V2 arginine vasopressin receptor antagonists.

Authors:
Maud J Urbanski Robert H Chen Keith T Demarest Joseph Gunnet Richard Look Eric Ericson William V Murray Philip J Rybczynski Xiaoyan Zhang

Bioorg Med Chem Lett 2003 Nov;13(22):4031-4

Drug Discovery, Johnson & Johnson Pharmaceutical Research & Development L.L.C., 1000 Route 202, Raritan, NJ 08869-0602, USA.

View Article and Find Full Text PDF
November 2003

Hepatic biotransformation of the new calcium-mimetic agent, RWJ-68025, in the rat and in man--API-MS/MS identification of metabolites.

Authors:
Wu-Nan Wu Linda A McKown Philip J Rybczynski Keith Demarest

J Pharm Pharmacol 2003 May;55(5):631-7

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Spring House, PA, USA.

View Article and Find Full Text PDF
May 2003

Benzoxazinones as PPARgamma agonists. part 1: SAR of three aromatic regions.

Authors:
Philip J Rybczynski Roxanne E Zeck Donald W Combs Ignatius Turchi Thomas P Burris Jun Z Xu Maria Yang Keith T Demarest

Bioorg Med Chem Lett 2003 Jul;13(14):2359-62

Johnson and Johnson Pharmaceutical Research and Development, LLC, 08869, Raritan, NJ, USA.

View Article and Find Full Text PDF
July 2003

Treatment of non-insulin-dependent diabetes mellitus.

Authors:
Mona Patel Philip J Rybczynski

Expert Opin Investig Drugs 2003 Apr;12(4):623-33

Room PC110, Bldg: PCC, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA.

View Article and Find Full Text PDF
April 2003